Press Release Summary: IMGENEX Corporation, a San Diego based company, has obtained exclusive world-wide rights to US Patent no. 5,830,451 from Brigham & Women\'s Hospital, Boston, to develop and market the EBI3-p35 fusion protein also known as Interleukin 35 (IL-35), for research purposes.
Press Release Body: IMGENEX Corporation, a San Diego based company, has obtained exclusive world-wide rights to US Patent no. 5,830,451 from Brigham & Women\'s Hospital, Boston, to develop and market the EBI3-p35 fusion protein also known as Interleukin 35 (IL-35), for research purposes. IL-35 is a novel IL-12 family cytokine produced by regulatory T cells (Treg) shown to suppress immune response through expansion of Treg cells.
Dr. Sujay Singh, President & CEO of IMGENEX, said that the license will allow IMGENEX to expand their presence in the regulatory T cell reagent market and facilitate new product development. \"href=\"http://www.imgenex.com/interleukin.php \"> IL-35 has been strongly implicated as a key player in regulating inflammatory processes. Securing this license will allow IMGENEX to expand its presence in a key market and sustain its role as an innovator in the life science industry.\"
For more information visit: http://www.imgenex.com Address:- Imgen Corporation 11175 Flintkote Avenue SAN DIEGO, CA 92121-1318 , US (858) 642-0978 Fax: 999 999 9999
Web Site: http://www.imgenex.com
Contact Details: Imgen Corporation 11175 Flintkote Avenue SAN DIEGO, CA 92121-1318 , US (858) 642-0978 Fax: 999 999 9999
2012
